Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Date
2014
Authors
Yeung, D.
Mauro, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Hematology. American Society of Hematology. Education Program, 2014; 2014(1):240-243
Statement of Responsibility
David T. Yeung, and Michael J. Mauro
Conference Name
Abstract
A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 × 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2015 by the American Society of Hematology